Hongkui Chen

Mr. Hongkui Chen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
HCHongkui Chen
Hongkui Chen
MZMin Zheng
Min Zheng
WZWenhui Zhang
Wenhui Zhang
YLYuan Long
Yuan Long
YXYu Xu
Yu Xu
MYMan Yuan
Man Yuan
Non-small-cell lung cancer (NSCLC) is known as one of the most lethal cancers, causing more than 1 million deaths annually worldwide. Therefore, the development of novel therapeutic drugs for NSCLC has become an urgent need. Herein, various mouse models provide great convenience not only for researchers but also for the development of antitumor drug. Meanwhile, TCM, as a valuable and largely untapped resource pool for modern medicine, provides research resources for the treatment of various diseases. Until now, cell-derived xenograft (CDX) model, patient-derived xenograft (PDX) model, syngeneic model, orthotopic model, humanized mouse model (HIS), and genetically engineered mouse models (GEMMs) have been reported in TCM evaluation. This review shows the role and current status of kinds of mouse models in antitumor research and summarizes the application progress of TCM including extracts, formulas, and isolated single molecules for NSCLC therapy in various mouse models; more importantly, it provides a theoretical exploration of what kind of mouse models is ideal for TCM efficacy evaluation in future. However, there are still huge challenges and limitations in the development of mouse models specifically for the TCM research, and none of the available models are perfectly matching the characteristics of TCM, which suppress the tumor growth through various mechanisms, especially by regulating immune function. Nevertheless, with fully functional immune system existing in syngeneic model and humanized mouse model (HIS), it is still suggested that these two models are more suitable for development of TCM especially for TCM extracts or formulas. Moreover, continued efforts are needed to generate more reliable mouse models to test TCM formulas in future research.

21 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MZManfang Zhu
Manfang Zhu
HCHongkui Chen
Hongkui Chen
XCxiaohua chen
xiaohua chen
YZYueyang Zhang
Yueyang Zhang
XCXiayu Chen
Xiayu Chen
XZXin Zhang
Xin Zhang
Background: In cancer immunotherapy, gene therapy has become a promising strategy through the introduction of immunostimulatory components into its formulation. However, ideal non-viral gene delivery platforms capable of simultaneously maintaining a high delivery efficiency and immune activation are still in demand. As an intestinal probiotic, Lactobacillus reuteri has potential correlation with cancer progression. Its unique antigenicity also confers its immunomodulatory activity. Method: We engineered a new non-viral siRNA delivery system, DMPLAC. By wrapping the lysate of Lactobacillus reuteri, it is expected to enhance the anti-cancer immunostimulatory properties. Result: Supported by certain internalization pathways, the prepared DMPLAC nanoparticles showed high siRNA delivery efficiency in vitro (up to 97.62%). They also strongly promoted the maturation and activation of immune cells, including dendritic and T cells, both in vitro and in vivo. By loading siRNA targeting the immune checkpoint CD47 gene, the DMPLAC/siCD47 complex strongly suppressed the growth of multiple colon cancer models through local administration with high safety. Conclusions: Our study developed a novel intestinal probiotic lysate-based gene delivery system with dual immunomodulatory abilities, suggesting a potential strategy for cancer immunotherapy.

1 July 2026 in Genes & Diseases
Verified
Journal Article
Open access
YZYuan-Yuan Zhang
Yuan-Yuan Zhang
KMKe Ma
Ke Ma
RZRen-Dong Zheng
Ren-Dong Zheng
HCHongkui Chen
Hongkui Chen
LLLiang Liang
Liang Liang
XZXin Zhang
Xin Zhang